广泛胸壁切除术后重建的新选择。

IF 2.2 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL
Clinics Pub Date : 2025-05-15 eCollection Date: 2025-01-01 DOI:10.1016/j.clinsp.2025.100679
João Paulo Cassiano de Macedo, Pedro Henrique Xavier Nabuco-de-Araujo, José Ribas M de Campos, Paulo M Pêgo-Fernandes, Ricardo M Terra
{"title":"广泛胸壁切除术后重建的新选择。","authors":"João Paulo Cassiano de Macedo, Pedro Henrique Xavier Nabuco-de-Araujo, José Ribas M de Campos, Paulo M Pêgo-Fernandes, Ricardo M Terra","doi":"10.1016/j.clinsp.2025.100679","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Chest wall reconstruction plays an important role in the outcomes of chest wall resection. However, there being a huge variety of materials at disposable, the best option has not yet been well defined. The Vitagraft® is a synthetic and absorbable material, that works as an osteoinduction and osteoconduction for bone regeneration. It consists of a β-phase Tricalcium Phosphate Ceramic (β-TCP) and the Polylactic Glycolic Acid Polymer (PLGA). Therefore, this study intends to assess the safety of Vitagraft® use in the chest wall.</p><p><strong>Methods: </strong>A prospective study, in which the patient's chest was reconstructed with Vitagraft®. Each patient was followed after the procedure for at least three months. The following variables were considered: KPS, ECOG, preoperative treatment, defect size, myocutaneous flap, the time between surgeries, complications, and mortality.</p><p><strong>Results: </strong>Eight resections were performed due to tumor findings. One reconstruction was a treatment for sternal cleft, another for Poland's syndrome, and finally as a consequence of late sternal dehiscence. Primary closure was performed in 63.6 % of the patients. Vitagraft® was used in association with mesh in eight cases. Reoperation was required in two cases, and prosthesis removal for one of them. Respiratory failure and major systemic complications were not evidenced.</p><p><strong>Conclusion: </strong>In the present study, the first to assess Vitagraft® in chest wall reconstruction, the second operation was necessary for 28 %, and removal was mandatory for 14 %. Until now, chest postoperative tomography has been showing good prosthesis biocompatibility. The authors need further details about the ossification time especially relating to the size of the resection.</p>","PeriodicalId":10472,"journal":{"name":"Clinics","volume":"80 ","pages":"100679"},"PeriodicalIF":2.2000,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12145752/pdf/","citationCount":"0","resultStr":"{\"title\":\"A new option of reconstruction after extensive chest wall resection.\",\"authors\":\"João Paulo Cassiano de Macedo, Pedro Henrique Xavier Nabuco-de-Araujo, José Ribas M de Campos, Paulo M Pêgo-Fernandes, Ricardo M Terra\",\"doi\":\"10.1016/j.clinsp.2025.100679\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>Chest wall reconstruction plays an important role in the outcomes of chest wall resection. However, there being a huge variety of materials at disposable, the best option has not yet been well defined. The Vitagraft® is a synthetic and absorbable material, that works as an osteoinduction and osteoconduction for bone regeneration. It consists of a β-phase Tricalcium Phosphate Ceramic (β-TCP) and the Polylactic Glycolic Acid Polymer (PLGA). Therefore, this study intends to assess the safety of Vitagraft® use in the chest wall.</p><p><strong>Methods: </strong>A prospective study, in which the patient's chest was reconstructed with Vitagraft®. Each patient was followed after the procedure for at least three months. The following variables were considered: KPS, ECOG, preoperative treatment, defect size, myocutaneous flap, the time between surgeries, complications, and mortality.</p><p><strong>Results: </strong>Eight resections were performed due to tumor findings. One reconstruction was a treatment for sternal cleft, another for Poland's syndrome, and finally as a consequence of late sternal dehiscence. Primary closure was performed in 63.6 % of the patients. Vitagraft® was used in association with mesh in eight cases. Reoperation was required in two cases, and prosthesis removal for one of them. Respiratory failure and major systemic complications were not evidenced.</p><p><strong>Conclusion: </strong>In the present study, the first to assess Vitagraft® in chest wall reconstruction, the second operation was necessary for 28 %, and removal was mandatory for 14 %. Until now, chest postoperative tomography has been showing good prosthesis biocompatibility. The authors need further details about the ossification time especially relating to the size of the resection.</p>\",\"PeriodicalId\":10472,\"journal\":{\"name\":\"Clinics\",\"volume\":\"80 \",\"pages\":\"100679\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2025-05-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12145752/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.clinsp.2025.100679\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.clinsp.2025.100679","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

摘要

目的:胸壁重建对胸壁切除术的疗效有重要影响。然而,由于一次性材料的种类繁多,最佳选择尚未得到很好的定义。Vitagraft®是一种可吸收的合成材料,作为骨诱导和骨传导用于骨再生。它由β相磷酸三钙陶瓷(β-TCP)和聚乳酸乙醇酸聚合物(PLGA)组成。因此,本研究旨在评估Vitagraft®在胸壁应用的安全性。方法:一项前瞻性研究,用Vitagraft®重建患者的胸部。每位患者术后随访至少三个月。考虑以下变量:KPS、ECOG、术前处理、缺损大小、肌皮瓣、手术间隔时间、并发症和死亡率。结果:因肿瘤发现行8例手术切除。一次重建是为了治疗胸骨裂,另一次是为了治疗波兰综合症,最后一次是由于晚期胸骨裂开。63.6%的患者进行了一期缝合。Vitagraft®与补片联合使用8例。其中2例需要再次手术,1例需要移除假体。未发现呼吸衰竭和主要的全身并发症。结论:在本研究中,第一次评估Vitagraft®胸壁重建,第二次手术是必要的,14%是强制性的。到目前为止,胸部术后断层扫描显示假体具有良好的生物相容性。作者需要进一步了解骨化时间,特别是与切除的大小有关的细节。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
A new option of reconstruction after extensive chest wall resection.

Objective: Chest wall reconstruction plays an important role in the outcomes of chest wall resection. However, there being a huge variety of materials at disposable, the best option has not yet been well defined. The Vitagraft® is a synthetic and absorbable material, that works as an osteoinduction and osteoconduction for bone regeneration. It consists of a β-phase Tricalcium Phosphate Ceramic (β-TCP) and the Polylactic Glycolic Acid Polymer (PLGA). Therefore, this study intends to assess the safety of Vitagraft® use in the chest wall.

Methods: A prospective study, in which the patient's chest was reconstructed with Vitagraft®. Each patient was followed after the procedure for at least three months. The following variables were considered: KPS, ECOG, preoperative treatment, defect size, myocutaneous flap, the time between surgeries, complications, and mortality.

Results: Eight resections were performed due to tumor findings. One reconstruction was a treatment for sternal cleft, another for Poland's syndrome, and finally as a consequence of late sternal dehiscence. Primary closure was performed in 63.6 % of the patients. Vitagraft® was used in association with mesh in eight cases. Reoperation was required in two cases, and prosthesis removal for one of them. Respiratory failure and major systemic complications were not evidenced.

Conclusion: In the present study, the first to assess Vitagraft® in chest wall reconstruction, the second operation was necessary for 28 %, and removal was mandatory for 14 %. Until now, chest postoperative tomography has been showing good prosthesis biocompatibility. The authors need further details about the ossification time especially relating to the size of the resection.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Clinics
Clinics 医学-医学:内科
CiteScore
4.10
自引率
3.70%
发文量
129
审稿时长
52 days
期刊介绍: CLINICS is an electronic journal that publishes peer-reviewed articles in continuous flow, of interest to clinicians and researchers in the medical sciences. CLINICS complies with the policies of funding agencies which request or require deposition of the published articles that they fund into publicly available databases. CLINICS supports the position of the International Committee of Medical Journal Editors (ICMJE) on trial registration.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信